Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms Beta-SPECIFIC-2
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 Jan 2021 Results of secondary analysis characterizing distinct gene signatures for treatment response and non-response to canakinumab in sJIA patients published in the Arthritis and Rheumatology
- 02 Mar 2018 Results pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046), were published in the Clinical and Experimental Rheumatology.
- 08 Nov 2017 Results of pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting